THE POSSIBLE ROLE OF ELECTRON-TRANSFER COMPLEXES IN THE ANTITUMOR ACTION OF AMSACRINE ANALOGS

被引:12
作者
BAGULEY, BC
机构
[1] Cancer Research Laboratory, University of Auckland Medical School, Auckland
基金
英国医学研究理事会;
关键词
Amsacrine; Antitumor action; Electron transfer; Ethidium; Topoisomerase II;
D O I
10.1016/0301-4622(90)80009-V
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Amsacrine is a DNA intercalating agent which is active against a number of tumours in mice and is used for the treatment of leukaemia in humans. In its DNA-bound form, amsacrine efficiently quenches the fluorescence of ethidium. Fluorescence lifetime studies demonstrate two populations of DNA-bound ethidium. The first, whose fluorescence lifetime is constant at approx. 3 ns and whose proportion increases with increasing amsacrine binding ratio, may comprise molecules bound in close proximity to amsacrine. The second, whose fluorescence lifetime is longer and variable (10-24 ns) and whose proportion decreases with increasing amsacrine binding ratio, may comprise molecules three or more base-pairs away from ethidium. Studies with a number of derivatives of 9-anilinoacridine containing different anilino substituents suggest that the observed wide variation in quenching capacity is correlated with the magnitude of the substituent dipole moment in a particular direction. Consideration of the geometry of the DNA-binding complex indicates that the negative pole of a dipole established in the anilino ring is directed towards a positively charged site on the ethidium molecule. Quenching of ethidium fluorescence may therefore occur where an electron-transfer complex has formed between ethidium and amsacrine molecules. To ascertain whether electron-transfer complex formation is biologically important in the amsacrine series, ethidium quenching has been quantitated and compared with activity against a transplantable neoplasm in mice, the Lewis lung carcinoma. Compounds which strongly quench ethidium fluorescence are in general highly active antitumour agents. The results are discussed in terms of a model where amsacrine has both a DNA-binding and a protein-binding domain, the latter possibly interacting by formation of an electron- transfer complex. The most likely protein-binding domain is on the enzyme topoisomerase II, the target for its cytotoxic activity. © 1990.
引用
收藏
页码:203 / 212
页数:10
相关论文
共 49 条
[1]   NUCLEIC-ACID BINDING-DRUGS .12. X-RAY CRYSTALLOGRAPHIC AND CONFORMATIONAL STUDIES ON THE ANTI-CANCER DRUG META-AMSA AND ITS MESYL DERIVATIVE [J].
ABRAHAM, ZHL ;
CUTBUSH, SD ;
KURODA, R ;
NEIDLE, S ;
ACHESON, RM ;
TAYLOR, GN .
JOURNAL OF THE CHEMICAL SOCIETY-PERKIN TRANSACTIONS 2, 1985, (03) :461-465
[2]  
ARLIN ZA, 1983, CANCER TREAT REP, V67, P967
[3]   QUENCHING OF THE FLUORESCENCE OF DNA-INTERCALATED ETHIDIUM-BROMIDE BY SOME TRANSITION-METAL IONS [J].
ATHERTON, SJ ;
BEAUMONT, PC .
JOURNAL OF PHYSICAL CHEMISTRY, 1986, 90 (10) :2252-2259
[4]   LASER FLASH-PHOTOLYSIS OF DNA-INTERCALATED ETHIDIUM-BROMIDE IN THE PRESENCE OF METHYLVIOLOGEN [J].
ATHERTON, SJ ;
BEAUMONT, PC .
JOURNAL OF PHYSICAL CHEMISTRY, 1987, 91 (15) :3993-3997
[5]   POTENTIAL ANTITUMOR AGENTS .41. ANALOGS OF AMSACRINE WITH ELECTRON-DONOR SUBSTITUENTS IN THE ANILINO RING [J].
ATWELL, GJ ;
REWCASTLE, GW ;
DENNY, WA ;
CAIN, BF ;
BAGULEY, BC .
JOURNAL OF MEDICINAL CHEMISTRY, 1984, 27 (03) :367-372
[6]   POTENTIAL ANTITUMOR AGENTS .48. 3'-DIMETHYLAMINO DERIVATIVES OF AMSACRINE - REDOX CHEMISTRY AND INVIVO SOLID TUMOR-ACTIVITY [J].
ATWELL, GJ ;
REWCASTLE, GW ;
BAGULEY, BC ;
DENNY, WA .
JOURNAL OF MEDICINAL CHEMISTRY, 1987, 30 (04) :652-658
[7]   RELATIONSHIP BETWEEN THE STRUCTURE OF ANALOGS OF AMSACRINE AND THEIR DEGREE OF CROSS-RESISTANCE TO ADRIAMYCIN-RESISTANT P388 LEUKEMIA-CELLS [J].
BAGULEY, BC ;
FINLAY, GJ .
EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1988, 24 (02) :205-210
[8]   COMPARISON OF INVIVO AND INVITRO DRUG SENSITIVITIES OF LEWIS LUNG-CARCINOMA AND P388-LEUKEMIA TO ANALOGS OF AMSACRINE [J].
BAGULEY, BC ;
WILSON, WR .
EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1987, 23 (06) :607-613
[9]   ANTI-TUMOR ACTIVITY OF SUBSTITUTED 9-ANILINOACRIDINES - COMPARISON OF INVIVO AND INVITRO TESTING SYSTEMS [J].
BAGULEY, BC ;
NASH, R .
EUROPEAN JOURNAL OF CANCER, 1981, 17 (06) :671-679
[10]  
BAGULEY BC, 1982, MOL PHARMACOL, V22, P486